Initial Oral Vinorelbine Dosing Schedules in Clinical Routine in Germany and Austria

Inclusion Criteria: * Written informed consent of the patient with regard to the pseudonymized documentation and processing of his/her disease data * Legally capable male or female NSCLC patient or legally capable female MBC patient; in both situations: ≥ 18 years of age (no upper limit) * Presence of any of the following two tumor entities: * Advanced NSCLC (stage III or IV) * Anthracycline- and taxane-resistant MBC (stage IV) in women * Planned systemic chemotherapy and planned regimen with oral vinorelbine in any palliative setting (decision on treatment must have been made before inclusion in this study); included treatments: * Monotherapy or any combination therapy with oral vinorelbine * Inclusion of patients with hybrid-treatment involving i.v. and oral vinorelbine in one treatment cycle is allowed Exclusion Criteria: * Presence of any contraindication with regard to oral vinorelbine treatment (and with regard to i.v. vinorelbine in case of hybrid-treatment) according to the respective Summary of Product Characteristics (SmPC) * Oral vinorelbine based palliative treatment already ongoing or planned oral vinorelbine starting dose of \>60 mg/m2 * Presence of a Eastern Cooperative Oncology Group (ECOG) performance status (PS) \> 2 * Simultaneous participation in an interventional clinical trial